Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease of childhood, encompassing a heterogeneous group of inflammatory arthritides that begin before the age of 16 and persist for at least six weeks. Unlike adult Rheumatoid Arthritis (RA), JIA is characterized by a high degree of clinical variability, a risk of permanent growth disturbances, and the potential for “silent” extra-articular complications like uveitis. For the pain physician and physiatrist, the goal is to balance aggressive inflammation control with a rehabilitative program that preserves joint function and prevents long-term disability.

1. Classification and Clinical Subtypes

The International League of Associations for Rheumatology (ILAR) classifies JIA into several distinct categories based on the number of joints involved and systemic symptoms during the first six months of the disease.

• Oligoarticular JIA: The most common subtype (approx. 50%). It affects four or fewer joints, typically large joints like the knee or ankle. These patients are at the highest risk for asymptomatic uveitis, requiring regular slit-lamp examinations.
• Polyarticular JIA (RF-Positive or RF-Negative): Affects five or more joints. The RF-positive subtype closely resembles adult RA and often carries a more aggressive prognosis.
• Systemic JIA (formerly Still’s Disease): Characterized by arthritis accompanied by a daily “quotidian” fever and a classic evanescent, salmon-pink rash. It is increasingly viewed as an autoinflammatory rather than autoimmune process.
• Enthesitis-Related Arthritis (ERA): Often affects the sites where tendons or ligaments attach to bone (entheses). It is frequently associated with the HLA-B27 marker and can progress to juvenile ankylosing spondylitis.

2. Pain Mechanisms in JIA: Inflammatory vs. Nociplastic

Pain in JIA is multifaceted and does not always correlate perfectly with the degree of joint swelling.

• Nociceptive/Inflammatory Pain: During flares, pro-inflammatory cytokines (IL-1, IL-6, and TNF-alpha) sensitize peripheral nociceptors within the synovium and joint capsule. This leads to the characteristic “morning stiffness” that improves with movement and warmth.
• Central Sensitization: Children with long-standing JIA can develop central sensitization (nociplastic pain). Even when the rheumatological markers (ESR, CRP) are normal and the joints appear quiet, the child may experience widespread pain, fatigue, and hyperalgesia due to the “winding up” of the central nervous system.
• Mechanical Pain: Chronic inflammation can lead to joint malalignment, limb-length discrepancies, and muscle atrophy, causing secondary mechanical pain in non-inflamed joints (e.g., hip pain due to a compensated gait from a stiff knee).

3. Pharmacological Management: The Stepwise Approach

The treatment paradigm has shifted from “bridging” with steroids to early aggressive therapy with disease-modifying antirheumatic drugs (DMARDs).

• NSAIDs: Provide symptomatic relief for pain and stiffness but do not prevent joint destruction.
• Methotrexate: The gold-standard DMARD for JIA. Clinicians must monitor for hepatic toxicity and provide folic acid supplementation.
• Biologic Agents: TNF-inhibitors (e.g., Etanercept, Adalimumab) and IL-6 inhibitors (e.g., Tocilizumab for systemic JIA) have revolutionized the treatment of refractory cases.
• Intra-articular Corticosteroid Injections (IACI): Frequently used in oligoarticular JIA to provide rapid relief and prevent the development of limb-length discrepancies.

4. Growth and Skeletal Complications

A critical board concept in JIA is the effect of inflammation on the growing skeleton.

• Hyperemia and Overgrowth: Chronic inflammation in a joint increases blood flow to the adjacent growth plate (epiphysis), which can cause that limb to grow longer than the unaffected side.
• Premature Closure: Conversely, severe, long-standing inflammation can lead to the premature fusion of the growth plate, resulting in a shorter limb.
• Micrognathia: Involvement of the temporomandibular joint (TMJ) can lead to impaired jaw growth, resulting in a “receding chin” appearance and significant dental and myofascial pain.

5. PM&R Integration: Functional Preservation

From a physiatric perspective, “remission” is defined by more than just the absence of swelling; it requires the restoration of age-appropriate function.

• Therapeutic Exercise: During flares, “rest” should be relative. Low-impact activities (swimming, cycling) are preferred over high-impact sports to maintain range of motion (ROM) without overstressing the articular cartilage.
• Splinting and Orthotics: Resting splints may be used at night to prevent flexion contractures (especially at the knee and wrist). Shoe lifts may be necessary to correct limb-length discrepancies and normalize pelvic mechanics.
• School Accommodations: Students may need a second set of textbooks to keep at home (to avoid heavy backpacks) or extra time for written assignments if the small joints of the hand are affected.

6. The “Silent” Threat: Uveitis

Perhaps the most high-yield “non-pain” fact for JIA boards is the risk of uveitis. Chronic anterior uveitis in JIA is typically asymptomatic and non-red. If left untreated, it can lead to cataracts, glaucoma, and permanent blindness. Screening frequency is determined by the patient’s ANA status and JIA subtype.

---

High-Yield Board “Fast Facts”

• Morning Stiffness: The hallmark of inflammatory pain; usually lasts >30 minutes in JIA.
• ANA (Antinuclear Antibody): A positive ANA in a child with oligoarticular JIA is the strongest predictor for the development of uveitis.
• Limb-Length Discrepancy: Can be caused by either growth plate acceleration (early) or premature fusion (late).
• Macrophage Activation Syndrome (MAS): A life-threatening complication of Systemic JIA characterized by cytopenias, high ferritin, and multi-organ failure.